# US 2022/0031837 A1 · Pneumococcal conjugate vaccine formulations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031837 A1
- Document ID: US20220031837A1
- Status: Published application
- Kind: A1
- Application number: 17/412,550
- Filed: 2021-08-26
- Published: 2022-02-03
- Earliest claimed: 2017-02-24
- Assignees: Merck Sharp & Dohme Corp.
- Applicants: Merck Sharp & Dohme Corp.
- Inventors: William J. Smith; Cecilia Giovarelli; Denise K. Nawrocki
- Web page: https://patentgrep.com/patent/US20220031837A1

## CPC

- A61K 9/10: Dispersions; Emulsions
- A61K 39/385: Haptens or antigens, bound to carriers
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/20: containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61K 47/36: Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K 47/6415: {Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins}
- A61K 47/646: {the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines}
- A61P 31/04: Antibacterial agents
- C07K 1/1072: {by covalent attachment of residues or functional groups}
- C07K 14/3156: {from Streptococcus pneumoniae (Pneumococcus) (Streptokinase C07K14/3153)}
- A61K 2039/55: {characterised by the host/recipient, e.g. newborn with maternal antibodies}
- A61K 2039/6037: {Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]}
- A61K 2039/70: {Multivalent vaccine}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention provides pneumococcal conjugate vaccine formulations comprising surfactant systems incorporating polysorbate 20 or a combination of a poloxamer and a polyol.

## Claims

### Claim 1

A formulation comprising (i) a 15-valent pneumococcal conjugate composition consisting essentially of S. pneumoniae polysaccharide from serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23 F and 33F, each conjugated to either CRM197 or diphtheria toxin fragment B (DTFB); (ii) a pH buffered saline solution having a pH in the range from 5.0 to 7.5; (ii) an aluminum salt; and (iv).

### Claim 2

(canceled)

### Claim 3

(canceled)

### Claim 4

(canceled)

### Claim 5

(canceled)

### Claim 6

(canceled)

### Claim 7

(canceled)

### Claim 8

(canceled)

### Claim 9

(canceled)

### Claim 10

(canceled)

### Claim 11

(canceled)

### Claim 12

(canceled)

### Claim 13

(canceled)

### Claim 14 (depends on 1)

The formulation of claim 1, wherein the final concentration of polysorbate 20 is equal to or greater than 0.07% weight/volume.

### Claim 15 (depends on 1)

The formulation of claim 1, wherein the final concentration of polysorbate 20 is in the range from 0.07% to 2.0% weight/volume.

### Claim 16 (depends on 1)

The formulation of claim 1, wherein the final concentration of polysorbate 20 is in the range from 0.1 to 0.2% weight/volume.

### Claim 17

(canceled)

### Claim 18

(canceled)

### Claim 19

(canceled)

### Claim 20 (depends on 1)

The formulation of claim 1, wherein the pH buffered saline solution has a pH in the range from 5.0 to 7.0.

### Claim 21 (depends on 20)

The formulation of claim 20, wherein the buffer is selected from the group consisting of phosphate, succinate, L-histidine, MES, MOPS, HEPES, acetate and citrate.

### Claim 22 (depends on 21)

The formulation of claim 21, wherein the buffer is L-histidine at a final concentration of 5 mM to 50 mM, or succinate at a final concentration of 1 mM to 10 mM.

### Claim 23 (depends on 22)

The formulation of claim 22, wherein the L-histidine is at a final concentration of 20 mM±2 mM.

### Claim 24 (depends on 1)

The formulation of claim 1, wherein the salt in the pH buffered saline solution is magnesium chloride, potassium chloride, sodium chloride or a combination thereof.

### Claim 25 (depends on 24)

The formulation of claim 24, wherein the salt in the pH buffered saline solution is sodium chloride.

### Claim 26 (depends on 25)

The formulation of claim 25, wherein the saline is present at a concentration from 20 mM to 170 mM.

### Claim 27

(canceled)

### Claim 28

(canceled)

### Claim 29 (depends on 1)

The formulation of claim 1, wherein the polysaccharides are conjugated to CRM197.

### Claim 30

(canceled)

### Claim 31

(canceled)

### Claim 32

(canceled)

### Claim 33

(canceled)

### Claim 34

(canceled)

### Claim 35

A formulation comprising a 15-valent pneumococcal conjugate composition consisting essentially of S. pneumoniae polysaccharide from serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23 F and 33F conjugated to CRM197; 20 mM Histidine pH 5.8; 150 mM NaCl; 250 μg/mL, APA; and 0.2% w/v polysorbate 20.

### Claim 36

A formulation comprising a 15-valent pneumococcal conjugate composition consisting essentially of S. pneumoniae polysaccharide from serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23 F and 33F conjugated to CRM197; 20 mM Histidine pH 5.8; 150 mM NaCl; 250 μg/mL APA; and 0.2% w/v polysorbate 20; formulated as a dosage form containing 4 μg/mL of each polysaccharide, except for the 6B polysaccharide which is at 8 μg/mL; and about 64 μg/mL CRM197 carrier protein.
